Denis Jérôme A, Mazzola Alessandra, Nguyen Guillaume, Lacorte Jean-Marc, Brochet Christine, Larsen Annette K, Conti Filoména
Sorbonne Universities, University Pierre et Marie Curie-Paris 6, Paris, France; Assistance Publique-Hôpitaux de Paris (AP-HP), Pitié-Salpêtrière Hospital, Department of Endocrine and Oncological Biochemistry, Paris, France; INSERM U938, Centre de recherche de Saint-Antoine, Cancer Biology and therapeutics, Paris, France.
Sorbonne Universities, University Pierre et Marie Curie-Paris 6, Paris, France; Assistance Publique-Hôpitaux de Paris (AP-HP), Pitié-Salpêtrière Hospital, Medical Unit of Hepatic Transplantation, Department of Hepato-Gastro-Enterology, 75013 Paris, France.
Clin Biochem. 2019 Feb;64:53-56. doi: 10.1016/j.clinbiochem.2018.10.009. Epub 2018 Oct 17.
CA 19-9 (carbohydrate antigen 19-9) is a tumor marker widely used for surveillance of patients with pancreatic cancer. However, even high levels of CA 19-9 may not necessarily be cancer-associated thereby complicating the diagnosis. This case report highlights a transient increase of CA 19-9 in a triple transplanted patient with cystic fibrosis and continuous immunosuppression for 20 years who was under antibiotics. This case emphasizes the need for a balanced interpretation of biological results, especially in cases where many confounding factors are present such as diabetes, chronic renal failure, cystic fibrosis and infections. This case also provides an opportunity to formulate a number of recommendations for the interpretation of tumor marker results in order to avoid long and costly further investigations.
CA 19-9（糖类抗原19-9）是一种广泛用于监测胰腺癌患者的肿瘤标志物。然而，即使CA 19-9水平很高也不一定与癌症相关，从而使诊断变得复杂。本病例报告强调了一名接受三联移植、患有囊性纤维化且持续免疫抑制20年并正在使用抗生素的患者，其CA 19-9出现短暂升高。该病例强调了对生物学结果进行平衡解读的必要性，尤其是在存在许多混杂因素的情况下，如糖尿病、慢性肾衰竭、囊性纤维化和感染。本病例还提供了一个机会，以制定一些关于肿瘤标志物结果解读的建议，以避免冗长且昂贵的进一步检查。
